Sanofi, page-18

When a big blue chip stock become interested in a micro-cap stock the pps usually explode and I definitely think Sanofi is more interested in the chronic respiratory disease management and possibly OSA (if they want to enter that market) instead of acute respiratory disease diagnosis (ResAppDx) which is more suited to telehealth platform so I think it will be a different source of revenue if Sanofi chose to work with RAP.
And if they announce their interest with an immediate $20M revenue, those 94M shares will easily get absorbed, PCK didn't have the potential Philips deal, hence the dumping didn't get absorbed and their pps dropped from the 20c discount for those shares when the pps was 25c to 12.5c.